US 12,252,524 B2
GIP/GLP1 co-agonist compounds
Jorge Alsina-Fernandez, Indianapolis, IN (US); Robert Andrew Brown, Carmel, IN (US); Mohamed ElSayed Hamed ElSayed, Fishers, IN (US); Hongchang Qu, Carmel, IN (US); Huyen Thanh Tran, Bargersville, IN (US); Aktham Aburub, Carmel, IN (US); and Phenil Jayantilal Patel, Carmel, IN (US)
Assigned to Eli Lilly and Company, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,998.
Application 17/366,998 is a division of application No. 16/518,468, filed on Jul. 22, 2019, granted, now 11,084,861.
Claims priority of provisional application 62/740,596, filed on Oct. 3, 2018.
Claims priority of provisional application 62/730,563, filed on Sep. 13, 2018.
Claims priority of provisional application 62/702,072, filed on Jul. 23, 2018.
Prior Publication US 2022/0048967 A1, Feb. 17, 2022
Int. Cl. C07K 14/605 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 38/56 (2006.01); A61P 3/04 (2006.01); A61K 9/00 (2006.01)
CPC C07K 14/605 (2013.01) [A61K 9/2013 (2013.01); A61K 9/4858 (2013.01); A61K 38/56 (2013.01); A61P 3/04 (2018.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01)] 20 Claims
 
1. A compound, or pharmaceutically acceptable salt thereof, wherein the compound is (D-Tyr)-Aib-EGTFTSDYSI-αMeL-LDKK((2-(2-(2-Amino-ethoxy)-ethoxyl-acetyl)2-(γGlu)-CO—(CH2)16—CO2H)AQ-Aib-EFIE-αMeY-LIAGGPSSGAPPPS-NH2 (SEQ ID NO:307).